Aureon Laboratories Inc., Pfizer deal

The companies will use Aureon's integrated systems pathology approach to establish quantitative biometrics for assessing prostate cancer patients' therapeutic response to neo-adjuvant androgen deprivation therapy (ADT). Ownership of resulting IP will be determined by inventorship, and Pfizer will have rights to use the resulting biometrics. Financial terms were not disclosed. ...